Abundant evidence has proven a higher predictive ability of the ApoB/ApoA1 ratio for CVDs [24,30], obesity, insulin resistance [20,21,27], and diabetes [22,31] over conventional biomarkers. This evidence concerns the gene APOB and obesity due to melanocortin 4 receptor deficiency.